Perspective Therapeutics (STU:AAJ0) Other Financing: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AAJ0 Perspective Therapeutics Inc STU:AAJ0
35 GF Score
Price €2.48
GF Value €0.68
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Other Financing?

Perspective Therapeutics STU:AAJ0 -0.24% 35 Other Financing is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:AAJ0 with a GF Score™ of 35/100 and a GF Value™ of €0.68 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Perspective Therapeutics's Other Financing for the three months ended in Jun. 2026 was €0.00 Mil.

Perspective Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil.

Perspective Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Other Financing Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Perspective Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 -0.00 -0.00 0.00
STU:AAJ0
35GF Score
Perspective Therapeutics Inc STU:AAJ0
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.00 Mil mean?
Perspective Therapeutics (STU:AAJ0) has a Other Financing of €0.00 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Other Financing too high?
Perspective Therapeutics' current Other Financing is €0.00 Mil. Overall, Perspective Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Other Financing compare to VMD and MOBI?
Perspective Therapeutics' Other Financing of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Perspective Therapeutics and its competitors. Perspective Therapeutics's current Other Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Perspective Therapeutics (STU:AAJ0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.68, compared to a current price of €2.48 — trading 264.1% above its estimated fair value. The current Other Financing is €0.00 Mil. Perspective Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Perspective Therapeutics (STU:AAJ0), the current Other Financing is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Perspective Therapeutics (STU:AAJ0) Overvalued in 2026?

Based on GuruFocus' analysis, Perspective Therapeutics stock appears to be overvalued. The current stock price of €2.48 is trading 264.1% above its estimated GF Value™ of €0.68. GuruFocus considers Perspective Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:AAJ0:

  • Other Financing: €0.00 Mil
  • GF Value™: €0.68 vs. price of €2.48 (264.1% above fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the STU:AAJ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Perspective Therapeutics Business Description

Other Exchanges CATX:USAAAJ0:Germany
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
35GF Score

Get the complete analysis for STU:AAJ0

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price
€0.68
GF Value